The Glycomic Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Glycomic Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

According to The Business Research Company’s Glycomic Therapeutics Global Market Report 2024, The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $141.31 billion in 2023 to $163.73 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increased awareness of glycan significance, rise in chronic diseases, drug development for rare diseases, collaborations in glycomics research..

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $301.03 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to expanding knowledge of glycan biology, precision medicine approaches, rising interest in immunotherapy, increased funding for rare diseases research, emergence of glycan biomarkers.. Major trends in the forecast period include expansion of glycomic applications in oncology, glycoengineering for enhanced therapeutic proteins, inclusion of glycomics in immuno-oncology, glycomics in rare and genetic disorders, regulatory considerations for glycomic drugs..

The increase in the prevalence of diabetes is expected to drive the growth of the glycomic therapeutics market. Diabetes is a chronic medical condition that affects the body's ability to regulate blood sugar (glucose) levels. In diabetes, alterations in glycans have been observed, which can contribute to insulin resistance and other metabolic abnormalities. Specific glycan patterns serve as biomarkers for diagnosing diabetes, predicting its progression, and monitoring treatment responses. For instance, in May 2023, according to the report published by the National Center for Health Statistics, a U.S.-based government agency that provides statistical information to guide actions and policies to improve the public health of the American people, the percentage of diagnosed diabetes for adults aged 18 and over, United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the increase in the prevalence of diabetes is driving the growth of the glycomic therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures
3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action
4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Product innovation is a key trend gaining popularity in the glycomic therapeutics market. Major companies operating in the glycomic therapeutics sector are focused on developing new technological and innovative solutions to strengthen their position in the market. For instance, in April 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company is discovering advanced therapies, launched a novel fixed-dose combination (FDC) of a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone to improve glycemic control and to reduce insulin resistance in type 2 diabetes patients.

The glycomic therapeutics market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Major Players:

F Hoffmann-La Roche Ltd.
Bayer AG
Sanofi SA
Thermo Fisher Scientific Inc.
GlaxoSmithKline PLC

Related Reports:

https://goodprnews.com/drone-package-delivery-market-size-analysis-industry/
https://goodprnews.com/farm-product-warehousing-and-storage-market-insights/
https://topprnews.com/drone-delivery-market-current-and-future-growth-analysis/
https://topprnews.com/farm-product-warehousing-and-storage-market-share/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]


Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model